HALO · Halozyme Therapeutics, Inc. · Share Buybacks
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-06-30 YTD | $332,729,000 | 10-Q, filed 2026-08-06 | ||
| 2025-12-31 | $342,372,000 | 10-K, filed 2026-02-17 | ||
| 2024-12-31 | $250,000,000 | 10-K, filed 2026-02-17 | ||
| 2023-12-31 | $402,383,000 | 10-K, filed 2026-02-17 | ||
| 2022-12-31 | $200,002,000 | 10-K, filed 2025-02-18 | ||
| 2021-12-31 | $350,058,000 | 10-K, filed 2024-02-20 | ||
| 2020-12-31 | $150,117,000 | 10-K, filed 2023-02-21 | ||
| 2019-12-31 | $199,998,000 | 10-K, filed 2022-02-22 | ||